Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RAPT THERAPEUTICS, INC.

(RAPT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/16/2021 09/17/2021 09/20/2021 09/21/2021 09/22/2021 Date
38.83(c) 39.47(c) 35.91(c) 35.36(c) 34.82 Last
313 489 1 178 375 292 849 219 324 291 356 Volume
+3.66% +1.65% -9.02% -1.53% -1.53% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 3,20 M - -
Net income 2021 -70,8 M - -
Net cash position 2021 187 M - -
P/E ratio 2021 -13,3x
Yield 2021 -
Sales 2022 1,04 M - -
Net income 2022 -100 M - -
Net cash position 2022 175 M - -
P/E ratio 2022 -10,9x
Yield 2022 -
Capitalization 1 043 M 1 043 M -
EV / Sales 2021 268x
EV / Sales 2022 835x
Nbr of Employees 69
Free-Float 97,3%
More Financials
Company
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. It has discovered and advanced two drug candidates... 
More about the company
Ratings of RAPT Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about RAPT THERAPEUTICS, INC.
09/20RAPT THERAPEUTICS : to Present at the 2021 Cantor Virtual Healthcare Conference
AQ
09/20RAPT THERAPEUTICS : to Present RPT193 Phase 1b Data at 30th European Academy of Dermatolog..
AQ
09/03RAPT Therapeutics to Present at Upcoming Investor Conferences
GL
08/15Certain Restricted Stock Unit of RAPT Therapeutics, Inc. are subject to a Lock-Up Agree..
CI
08/15Certain Stock Options of RAPT Therapeutics, Inc. are subject to a Lock-Up Agreement End..
CI
08/15Certain Common Stock of RAPT Therapeutics, Inc. are subject to a Lock-Up Agreement Endi..
CI
08/12RAPT THERAPEUTICS : SVB Leerink Starts RAPT Therapeutics at Outperform With $49 Price Targ..
MT
08/11RAPT THERAPEUTICS : Q2 Net Loss Widens, Revenue Falls
MT
08/11RAPT THERAPEUTICS : Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
08/11RAPT THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Result..
AQ
08/11RAPT THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
08/11RAPT THERAPEUTICS : Earnings Flash (RAPT) RAPT THERAPEUTICS Reports Q2 Revenue $869,000
MT
08/11RAPT Therapeutics Reports Second Quarter 2021 Financial Results
GL
08/11RAPT Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Secon..
CI
07/07RAPT THERAPEUTICS : UBS Adjusts RAPT Therapeutics' Price Target to $55 From $23, Citing RP..
MT
More news
News in other languages on RAPT THERAPEUTICS, INC.
06/15Hoy en Wall Street: Inflación y pricing power
More news
Analyst Recommendations on RAPT THERAPEUTICS, INC.
More recommendations
Chart RAPT THERAPEUTICS, INC.
Duration : Period :
RAPT Therapeutics, Inc. Technical Analysis Chart | RAPT | US75382E1091 | MarketScreener
Technical analysis trends RAPT THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 34,82 $
Average target price 62,14 $
Spread / Average Target 78,5%
EPS Revisions
Managers and Directors
Brian Russell Wong President, Chief Executive Officer & Director
Rodney K. B. Young CFO, Secretary & Principal Accounting Officer
William J. Rieflin Chairman
William Ho Chief Medical Officer
Dirk G. Brockstedt Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
RAPT THERAPEUTICS, INC.79.04%1 043
GILEAD SCIENCES, INC.23.12%89 936
BIONTECH SE318.73%82 443
WUXI APPTEC CO., LTD.36.63%69 407
REGENERON PHARMACEUTICALS33.91%67 262
VERTEX PHARMACEUTICALS-21.38%48 202